Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Latest developments in symptomatic treatment of Parkinson’s disease

Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, speaks on the latest research into symptomatic treatment of Parkinson’s disease. Levodopa is a very successful therapy, however, its short half-life introduces challenges in drug administration. A new, slow-release preparation technique has recently been approved in the US, improving this therapy option. Prof. Stocchi mentions sublingual apomorphine and inhaled levodopa as two newly released drugs for rescue therapy. To achieve more continuous delivery of the drug, subcutaneous preparations of levodopa and the use of an oral delivery system, for continuous release during the day, are currently being studied. Tavapadon, a new dopamine antagonist, aims to overcome the challenge of side effects shown with previous dopamine antagonists. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.


Sunovion, Neuroderm, Abbvie, Britannia, Lusofarmaco, Ever Pharma, BIAL Pharma, Roche, Biogen, IRLAB, Chiese Ltd., GlaxoSmithKline Plc., Impax Laboratories Inc., Lundbeck Ltd., Teva UK Limited, UCB Pharma Ltd., Merck & Co. Inc, Zambon Pharma, Novartis AG